Related Experiment Video
Updated: Jul 17, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Advances in Anti-Inflammatory Therapeutics: 20-21 November 2006, London, UK
1Discovery Bioscience, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire, LE11 5RH, UK. martin.braddock@astrazeneca.com
Abstract:
This meeting highlighted early discovery to early clinical development of anti-inflammatory drugs. New compounds included kinase inhibitors, receptor modulators and an extended use for an existing drug, lenalidomide, in a further indication. Risk mitigation strategies to improve the likelihood of clinical success was a dominant feature of the meeting.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

